Holen Sie sich die Stockscreener-App
2.71
1.45%
-0.04
Vorhandelsmarkt:
2.58
-0.13
-4.80%
Silexion Therapeutics Corp Aktie (SLXN) Neueste Nachrichten
SLXN Q1 2026 Earnings: Narrowed Loss Beats Estimates with 35.4% EPS SurpriseAnalyst Drop Coverage - newsline.com
Silexion Therapeutics (NASDAQ: SLXN) registers up to 859,609 resale shares - Stock Titan
Silexion Therapeutics Warrants (SLXNW) Plunge 33% as Support at $0.03 Faces TestValue Factor - newsline.com
Silexion Therapeutics Corp Ord Stock Short Interest Falls to 43.76% - Quiver Quantitative
SLXN Q1 2026 Earnings: Narrowed Loss Per Share Surprises, Stock GainsCapex Guidance - newsline.com
Number of shareholders of Silexion Therapeutics Corp – NASDAQ:SLXN - TradingView
Silexion (SLXN) awards CSO 6,000 RSUs after reverse share split - Stock Titan
[Form 4] Silexion Therapeutics Corp Insider Trading Activity - Stock Titan
Silexion (SLXN) CEO granted 10,000 shares; holdings rise to 16,547 - Stock Titan
Silexion Therapeutics Corp (SLXN) Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline ProgressesGross Profit Margin - newsline.com
Number of shareholders of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView
Silexion (SLXN) asks shareholders to OK 399,020 warrants and a capital increase - Stock Titan
Silexion Stock Just Split 1-for-10. The Real Test Starts Now - Bez Kabli
Silexion Therapeutics Implements 1-for-10 Reverse Share Split - The Globe and Mail
Moringa (SLXN) discloses 1,382,346-share Silexion stake and contests note issuances - Stock Titan
- newsline.com
Silexion Therapeutics Corp Files Form 8-K: NASDAQ Listing, Company Details, and Warrant Information - Minichart
Silexion Therapeutics (SLXN) completes 1-for-10 reverse split, adjusts warrant terms - Stock Titan
SLXN Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplinePreliminary Results - thelegaladvocate.com
Silexion Therapeutics announces 1-for-10 reverse share split - MSN
Silexion Therapeutics (SLXN) Slips 3% as Shares Test Key Support at $0.40Shakeout Pattern - thelegaladvocate.com
Silexion Therapeutics Corp Warrant (SLXNW) Faces Continued Selling Pressure at Penny LevelRevenue Weighted - newsline.com
Silexion Therapeutics Announces Reverse Split to Maintain Listing - The Globe and Mail
SLXN Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineWeak Earnings Momentum - newsline.com
Silexion Therapeutics Begins GMP Manufacturing of SIL204 and Receives Approval for Phase 2/3 Trial at Tel Aviv Sourasky Medical Center - geneonline.com
Silexion announces 1-for-10 reverse stock split effective Thursday By Investing.com - Investing.com Australia
Silexion Therapeutics Announces 1-For-10 Reverse Share Split - TradingView
Silexion announces 1-for-10 reverse stock split effective Thursday - Investing.com
Silexion Therapeutics to implement 1-for-10 reverse share split, effective May 29, 2026 - TradingView
Silexion (NASDAQ: SLXN) plans 1-for-10 reverse share split to aid Nasdaq compliance - Stock Titan
Silexion Therapeutics Announces 1-for-10 Reverse Share Split - Moomoo
Silexion Therapeutics Corp Warrant (SLXNW) Struggles Near $0.02: Low Volume and Narrow Trading RangeMutual Fund Flow - newsline.com
Silexion Therapeutics (SLXN) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionCore Business Growth - newsline.com
Silexion Therapeutics (SLXN): Modest Gains as Stock Holds Key Support at $0.46Percent Above MA - Newser
SLXN Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Surprise but Stock DeclinesFinal Results - newsline.com
Silexion Therapeutics prices new warrants exercise deal at $0.50 to raise $1M - MSN
Silexion Therapeutics Stock Surges 97% on Phase 2/3 Trial Approval - Meyka
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN - TechStock²
Silexion Therapeutics(SLXN) Stock Options Chain | Quotes & News - Moomoo
Biotech Stock Silexion Therapeutics Corp. (NASDAQ: SLXN) Soars on Update and First Quarter Results - Investorideas.com
Silexion Therapeutics (SLXN) spikes as investors react to mid-May clinical-trial milestones and fresh financing - Quiver Quantitative
Silexion’s Cancer Trial Push Puts Focus on Cash - TechStock²
Silexion Therapeutics Posts Wider Q1 Loss, Advances SIL204 Into Phase 2/3 Trials; Stock Up - RTTNews
Silexion Therapeutics (SLXN) Gained +56.13% — Can It Break $0.44? 2026-05-20MAMA Signal - Newser
Silexion (NASDAQ: SLXN) 10-K amendment corrects internal control date - Stock Titan
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):